PeptideCompareWhat research peptides are actually used for — a landscape far broader than any single product page.
Peptides are studied across ageing biology, analytical chemistry, drug development and regulatory science — often for reasons that have little to do with each other beyond the shared chemistry. This overview sets out that broader landscape, using the same evidence standards applied throughout this encyclopedia.
- Peptides are studied for reasons that rarely overlap: ageing biology, purity verification, drug development and regulatory science all use them differently.
- For several widely discussed peptides, including MOTS-c, essentially all published data comes from animal studies — no published research has measured the effect of administering it to humans.
- Verifying what is actually in a vial — HPLC identity testing, a proper Certificate of Analysis — is a distinct scientific discipline, separate from studying what a peptide does.
- Regulatory treatment of peptides is genuinely in motion: the same substances can be reclassified, reviewed and voted on by advisory bodies within a single year.
- A small number of peptides — the GLP-1 class most visibly — have completed the full route from laboratory discovery to an approved medicine; most peptides discussed today have not.
Ageing and cellular research
A significant share of current peptide research concerns how cells age, repair themselves and communicate. MOTS-c and humanin are both mitochondrial-derived peptides — encoded by mitochondrial DNA rather than the nuclear genome — which gives them a distinct research angle on mitochondrial health, a central theme in ageing biology. The caveat belongs alongside the interest: for MOTS-c, essentially all available data comes from mouse studies, and no published study has measured its effect after administration to humans.
Epitalon follows a different line of research, tied to telomerase activity, but the published literature on it is dominated by a single source — the St. Petersburg Institute of Bioregulation and Gerontology — without independent replication in the West. Neither observation says whether these peptides are effective or not: it says that “extensively studied” and “independently confirmed” are different claims, and the difference is exactly what a careful reading of peptide research should track.
The science behind verifying purity
Before a peptide becomes useful for any kind of research, what is actually in the vial has to be established — a discipline in its own right. HPLC (high-performance liquid chromatography) separates and identifies the compound and any impurities; a Certificate of Analysis (COA) is the lab report that records that result for a specific batch: purity percentage, identity confirmation, sometimes heavy-metal and endotoxin screening as well. Independent labs that specialise in this kind of testing — names such as Janoshik, VLAB and Liquilabs recur across the European market — are themselves analytical-chemistry businesses: a peptide there serves as a reference standard for calibrating equipment, not as the object of study.
A 2024 study illustrates why the distinction matters in practice: peptides purchased from online sellers without a prescription measured between 7.7% and 14.4% purity against a labelled 99%.
A regulatory landscape that keeps shifting
Peptides sit inside a regulatory environment that is itself worth following. In the United States, the FDA placed nineteen peptides on a restrictive list for pharmacy compounding in 2023. That decision has been under active review since: in July 2026, an FDA advisory committee met over two days to vote, substance by substance, on whether seven of them should be recommended for a legal compounding pathway — a process built from public comment, scientific briefing documents and a formal vote, a considerably more layered picture than a simple “legal” or “not legal.” Europe has no directly comparable process, which is itself worth noting: the same substances move through a different regulatory structure here, with different actors and a different pace.
Understanding this landscape means following not only the biology, but this kind of institutional decision-making — it ultimately determines through which channels a substance can become legally and safely available at all.
Distinct research areas, not one peptide story
“Peptides” is not a category with a single purpose. It is a class of molecules studied for reasons that are often entirely disconnected from one another:
How that research actually proceeds
Studying a peptide rarely starts with a human trial. The typical path runs through cell-culture models — how the substance binds a receptor, what happens inside the cell — then animal models (efficacy, toxicology, pharmacokinetics: how quickly something is cleared, how it is absorbed), and only after years, sometimes never, into human clinical trials. For most peptides discussed today, the published science stops somewhere in those first two stages. That is not necessarily a problem; it is simply where the research currently stands, and it is why an honest evidence grade — animal versus human, small versus large study, replicated versus one-off — matters as much as the underlying claim.
The clinical route, where research does reach patients
Alongside this research landscape, a legal, controlled route also exists through which some peptides genuinely reach patients: compounding pharmacies working from an individual prescription. That is a fundamentally different setting from the research vials sold online — with quality control, physician oversight and a legal framework — and it is precisely the pathway that the regulatory process described above ultimately governs.
The evidence tiers used throughout this encyclopedia — human, animal or estimate — exist for exactly this reason. A peptide can be genuinely studied, and still have no data on what happens when a human receives it. Both facts belong in the same sentence.
Sources
- Mitochondrial-derived peptides and healthy ageing. Physiological Reports, 2019 (PMC6640593) — reported effects come from mouse models; no published data exists for administration in humans. www.ncbi.nlm.nih.gov
- Hashimoto Y et al. A rescue factor abolishing neuronal death by a wide spectrum of familial Alzheimer’s disease genes and Aβ. PNAS, 2001 (PMID 11371648) — the original identification of humanin. pubmed.ncbi.nlm.nih.gov
- Khavinson VK. Peptides and ageing. Mechanisms of Ageing and Development, 2000. doi.org
- Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. Journal of Medical Internet Research, 2024 — measured purity ran from 7.7% to 14.4% against a labelled 99%. www.ncbi.nlm.nih.gov
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration, 2026. www.fda.gov
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences, 2018 (PMID 29986520). pubmed.ncbi.nlm.nih.gov
- Dolotov OV et al. Semax, an analogue of ACTH(4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat hippocampus. Neuroscience Letters, 2003 (PMID 14556513). pubmed.ncbi.nlm.nih.gov
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Frontiers in Pharmacology, 2022 — elimination half-life under 30 minutes in both species; no published human pharmacokinetic data. www.ncbi.nlm.nih.gov
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021 (PMID 33567185). pubmed.ncbi.nlm.nih.gov